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Abstract
Background: There are limited data on the evolution of the leukocyte and platelet counts in malaria patients.
Methods:  In a clinical trial of chloroquine vs. chloroquine plus doxycycline vs. doxycycline alone against
Plasmodium vivax (n = 64) or Plasmodium falciparum (n = 98) malaria, the total white cell (WCC) and platelet (PLT)
counts were measured on Days 0, 3, 7 and 28 in 57 indigenous Papuans with life long malaria exposure and 105
non Papuan immigrants from other parts of Indonesia with limited malaria exposure.
Results: The mean Day 0 WCC (n = 152) was 6.492 (range 2.1–13.4) × 109/L and was significantly lower in the
Papuans compared to the non Papuans: 5.77 × 109/L vs. 6.86 × 109/L, difference = -1.09 [(95% CI -0.42 to -1.79
× 109/L), P = 0.0018]. 14 (9.2%) and 9 (5.9%) patients had leukopaenia (<4.0 × 109/L) and leukocytosis (>10.0 ×
109/L), respectively. By Day 28, the mean WCC increased significantly (P = 0.0003) from 6.37 to 7.47 × 109/L (73
paired values) and was similar between the two groups. Ethnicity was the only WCC explanatory factor and only
on Day 0.
The mean Day 0 platelet count (n = 151) was 113.0 (range 8.0–313.0) × 109/L and rose significantly to 186.308 ×
109/L by Day 28 (P < 0.0001). There was a corresponding fall in patient proportions with thrombocytopaenia
(<150 × 109/L): 119/151 (78.81%) vs. 16/73 (21.92%, P < 0.00001). Papuan and non Papuan mean platelet counts
were similar at all time points. Only malaria species on Day 0 was a significant platelet count explanatory factor.
The mean D0 platelet counts were significantly lower (P = 0.025) in vivax (102.022 × 109/L) vs. falciparum
(122.125 × 109/L) patients.
Conclusion: Changes in leukocytes and platelets were consistent with other malaria studies. The Papuan non
Papuan difference in the mean Day 0 WCC was small but might be related to the difference in malaria exposure.
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Background
The malaria induced changes in the total white cell (WC)
and platelet (PLT) counts have been documented in sev-
eral clinical series of vivax and falciparum malaria in
malaria immune and naïve patients of all ages [1-9],
describing mostly the WC and PLT counts at presentation.
The majority of malaria patients at presentaiton have total
WCCs in the normal range. Leukopaenia may affect up to
15% (WCC < 4 × 109/L) of malaria infected adults
[3,4,8,10] and was present in ~10% of 1,369 hospitalized
Kenyan children with moderately severe or severe falci-
parum malaria (WCC < 6.1 × 109/L) [6]. Rates of leukocy-
tosis (>10 × 109/L) in adults range between 1 and ~7%
[1,3,4,9,11,12] and was 20% in the hospitalized Kenyan
children (>16.5 × 109/L) [6]. Reported, malaria induced
changes in the differential white cell counts include neu-
tropaenia, neutrophilia, immature neutrophils (left shift),
neutrophil toxic granulation, lymphopaenia, lymphocy-
tosis, atypical lymphocytes, monocytosis, eosinopaenia,
post treatment eosinophilia, and leukaemoid reactions
[3-5,10,11,13-19]. The underlying mechanisms include a
shift in neutrophils from the circulatory to the marginal
pool to sites of inflammation, splenic localisation, serum
lymphotoxic factors, and intercurrent bacterial infections
[13,15,20-23]. In experimentally induced falciparum
malaria, Aotus monkeys had an increase in the absolute
neutrophil counts seven days post infection that was fol-
lowed by neutropaenia by Day 14; the reverse was found
for the lymphocyte counts [24]. Ethnicity, sex and
immune status may also be relevant factors affecting the
leukocyte count. Leukocytosis was more common in Plas-
modium vivax infected African American soldiers (27%)
compared to Caucasian soldiers (9%) but the latter had
higher rates (47 vs. 26%) of relative lymphocytosis (lym-
phocyte count > 35%) [14]. Studies in temperate climates
have found that individuals of African origin tend to have
lower total leukocyte, neutrophil and platelet counts com-
pared to Caucasians and women have higher leukocyte
and neutrophil counts than men [25,26]. Malaria naive
Sri Lankans infected with P. vivax had higher mean lym-
phocyte counts and significantly raised gamma/delta T
cells during fever paroxysms compared to malaria
immune vivax patients, suggesting a greater inflammatory
response by the non immune patients [27]. Similarly,
TNFα levels were greater in non immune Sri Lankans with
P. vivax [28].
Studies examining trends in the total WCC are few. One
study of experimentally induced falciparum malaria in
non immune Americans showed an initial fall in the
mean WCC reaching a nadir on Day 3 and rising thereaf-
ter to baseline values by study end [2]. Studies in African
children have shown modest falls in the mean total WCC
over 7 to 14 days whilst another study found that acutely
ill falciparum infected children had a significant fall in the
mean neutrophil count on Day 3 [29-31].
Malaria induced thrombocytopaenia (platelet count <
150 × 109/L) is very common, affecting between 40–85%
of patients [4,7-9,32-35]. Moderate (50–100 × 109/L) and
severe (<50 × 109/L) thrombocytopaenia occur in 30–50
and 6–16%, respectively [4,5,7,30,35]. Thrombocytopae-
nia improves with disease resolution and the platelet
count is generally normal within seven days [34,35] but
ranged from 2–28 days in one series [35]. Considerable
overlap exists between the platelet counts of the different
malaria species and between uncomplicated and severe
falciparum malaria. Two studies suggest that a lower
platelet count may be an indicator of higher biomass fal-
ciparum and vivax infections [36,37] but Eriksson et al did
not find this correlation [4]. Factors associated with
malaria induced thrombocytopaenia include splenomeg-
aly, splenic sequestration and platelet removal by macro-
phages [38-40]. The role of antiplatelet antibodies is
unclear [34,41,42].
In north east Papua, indigenous Papuans have life long
exposure to malaria whereas Indonesians who immigrate
to Papua usually contract malaria for the first time in
Papua [43]. Whether this difference in malaria exposure
affects the white cell and platelet counts in diseased
patients is unknown. This paper presents data from a clin-
ical trial on the evolution of the total white cell and plate-
let counts and explores possible Papuan non Papuan
differences.
Materials and methods
Malariometric data from this area of northeast Papua and
study conduct are detailed elsewhere [44,45]. Briefly,
indigenous adult Papuans (n = 57) and non Papuan (n =
105) adults from other parts of Indonesia were recruited
into a hospital based, 28 days, clinical trial comparing
chloroquine vs. chloroquine plus doxycycline vs. doxycy-
cline for the treatment of parasitologically proven
(Giemsa stained thick and thin blood films) acute uncom-
plicated falciparum and acute vivax malaria. There was no
minimum parasitaemia for either species but a maximum
of 150,000/μL asexual falciparum forms/μL for study
entry. Recruited patients underwent a history, a detailed
physical examination (including an abdominal examina-
tion to detect hepatosplenomegaly) and supervised treat-
ment. Giemsa stained blood films were taken and read on
Days 0–7, 14, 21, 28 and a blood count (Hb, total WCC,
platelet count) was performed on Days 0, 3, 7, and 28; a
manual differential white cell count was not done. Dou-
ble entered, validated data were analysed using Epi Info
6.04b (Centers for Disease Control and Prevention,
Atlanta, GA, USA) and Stata v 8 (Stata Corporation, USA).
Normally distributed data were compared using the stu-Malaria Journal 2008, 7:259 http://www.malariajournal.com/content/7/1/259
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dent's 't' test or ANOVA or the Mann-Whitney U or
Kruskall-Wallis for skewed data. Spearman's rank correla-
tion was used to determine the relationship between
skewed continuous data. Proportions were compared
using uncorrected chi squared values. Multivariate analy-
ses were performed to assess the independence of ethnic-
ity, splenomegaly, gender, malaria species and drug
regimen on the total white cell and platelet counts. A P
value of ≤ 0.05 was considered significant; no adjustment
was made for multiple comparisons. Written informed
consent was obtained from all patients. The study was
conducted according to the Indonesian Ministry of
Health, the Indonesian Navy, and the United States Navy
and Army regulations governing the protection of human
subjects.
Results
A total of 162 malaria infected patients were recruited into
the study: P.vivax (n = 63), P. falciparum (n = 89), and
mixed infections (n = 10). Based on the dominant species,
the 10 mixed infections were reclassified as vivax (n = 1)
or falciparum (n = 9) malaria. Males (aged 15 to 44),
numbered 146 (~90%), and women (aged 15 to 33) 16
(~10%). The Papuans numbered 57; the 105 non
Papuans came from Java (n = 54), Sulawesi (n = 28),
Ambon (n = 9), Bali (n = 7), Sumatera (n = 5), and other
islands (n = 2). Median Papuan and non Papuan [inter-
quartile (IQ) range] residential times in Papua were 21.5
(18 to 24) and three (1 to 5) years, respectively (P <
0.0001). 152/162 (93.8%) had blood results available for
Day 0 and 74 patients completed the study to Day 28.
Splenomegly was more common in the Papuans, 26/57
(45.6%), compared to the non Papuans, 27/105 (25.7%),
for a relative risk of 1.8 [95% confidence interval (CI) 1.15
to 2.7].
Day 0 total white cell counts
The Day 0 total WCCs ranged from 2.1–13.4 × 109/L with
a median and mean of 6.3 and 6.492 × 109/L, respectively.
Leukopaenia (WCC < 4 × 109/L) was present in 14
patients (9.2%); their WCCs ranged from 2.1–3.9 × 109/L.
Nine (5.9%) patients had a leukocytosis (WCC > 10 ×
109/L). Thus, the majority of patients, ~85%, had a nor-
mal total WCC at presentation. In the multivariate analy-
sis, only ethnicity was a significant explanatory variable
for the total WCC on Day 0. The mean Day 0 total WCC
was significantly lower in the Papuans (5.7 × 109/L) com-
pared to the non Papuans (6.8 × 109/L): difference = -1.09
[(95% CI -0.42 to -1.79 × 109/L), P = 0.0018]. There was
a positive correlation between the Day 0 WCC and the P.
vivax parasitaemia (Sp rho = 0.43, P = 0.0003) but no cor-
relation between the Day 0 WCCs and: (i) the Day 0 falci-
parum counts [Spearman's (Sp) rho = 0.139, P = 0.19],
(ii) the Day 0 temperature (Sp rho = -0.0066, P = 0.94),
and (iii) the Day 0 platelet count (Sp rho = 0.125, P =
0.12).
Evolution of the total white cell counts
The changes in the mean white cell counts during follow
up were similar for both malaria species and ethnic
groups (Figures 1 and 2). Compared to baseline, the fall
in the mean total WCC on Day 3 was significant in the
non Papuans: (i) Pf: -0.898 (5.735 – 6.633) × 109/L (P =
0.0015), (ii) Pv: -1.069 (6.132 – 7.201) × 109/L (P =
0.0012). The mean Day 3 Day 0 difference between the
non Papuans and Papuans was also significantly different
The mean (95% CI) total white cell counts in falciparum infected Papuan and non Papuan patients Figure 1
The mean (95% CI) total white cell counts in falciparum infected Papuan and non Papuan patients.
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[Pf: -0.898 vs. 0.248 × 109/L (P = 0.008), Pv: -1.069 vs.
0.626 × 109/L (P = 0.0054)].
By Day 28, the number of evaluable patients had fallen to
74. The mean total WCC was: (i) significantly higher com-
pared to baseline (n = 73 pairs) 7.47 vs. 6.37 × 109/L: dif-
ference = 1.1 (0.52 – 1.69) × 109/L, P = 0.0003] and (ii)
similar between the Papuans [7.79 × 109/L (n = 27)] and
the non Papuans [7.3 × 109/μL (n = 47)] but there was a
trend towards a higher mean change in the Papuans com-
pared to the non Papuans: 1.8 vs. 0.7 × 109/L (P = 0.07).
There was no Day 28 leukopaenia but five (6.7%) patients
had leukocytosis. Their Day 28 Day 0 matching values (x
109/L) were: 10.4–3.4, 10.8–6, 12–7.2, 12.2–9.2, 16.4–7.
They were all aparasitaemic, afebrile, and discharged clin-
ically well from the hospital.
Day 0 platelet counts
The Day 0 platelet counts (PLT0) for all patients com-
bined varied widely, ranging from 8–313 × 109/L (IQ
range 76 to 141 × 109/L); the median and mean values
were 102 and 113 × 109/μL, respectively. The majority of
patients, 119/151 (78.8%), had thrombocytopaenia
(<150 × 109/L); 43.7% (66/151) had moderate thrombo-
cytopaenia (50–100 × 109/L). Five P. falciparum and eight
had P. vivax (8.6%) infeted patients were severely throm-
bocytopaenic (<50 × 109/μL) but none had clinical signs
of bleeding. Of the 88 patients who had urine dipstick
tests, nine (10.2%) had microscopic haematuria (vivax =
4, falciparum = 5); the platelet counts in these nine ranged
from 50–313 (median 101) × 109/L.
The multivariate analysis showed that only the malaria
species was a significant independent variable to explain
the Day 0 platelet count. The mean PLT0 was significantly
lower (P = 0.025) in the vivax patients: 102.022 vs.
122.125 × 109/L. The PLT0 was negatively correlated with
the Day 0 falciparum parasitaemia (Sp rho = -0.29, P =
0.005) but not with the Day 0 vivax parasitaemia (Sp rho
= -0.0984, P = 0.4). There was also a significant negative
correlation with the Day 0 temperature (Sp rho = -0.21, P
= 0.009) and the PLT0 in the vivax patients (Sp rho = -
0.26, P = 0.04) and a negative trend in falciparum patients
(Sp rho = -0.18, P = 0.097).
Evolution of the platelet counts
The proportion of thrombocytopaenic patients declined
over time: 78.8% (119/151) on D0, 74.26% (101/136)
on D3, 23.62% (30/127) on D7 and 21.92% (16/73) on
Day 28 (P < 0.0001, chi2 for trend). By Day 28, the mean
platelet count was significantly higher compared to base-
line: 188.308 vs. 108.056 × 109/L (P < 0.0001), and
ranged from 47.0 to 318.2 (IQ range 153 to 226) × 109/L
(Figures 3, 4 and 5). The mean D28-D0 changes in platelet
counts were not significantly different between the
Papuans and non Papuans: 83.280 vs. 75.576 × 109/L (P
= 0.6). The mean Day 7 platelet count was significantly
higher than that of Day 28 only in the vivax infected non
Papuans (n = 21): 175.819 vs. 251.238 × 109/L (P =
0.0036). The multivariate analyses were unremarkable,
except for drug arm as a PLT7 explanatory factor. This was
accounted for by the combination vs. the doxycycline
arm: 235.463 vs 191.741 × 109/L (P = 0.029).
The mean (95% CI) total white cell counts in vivax infected Papuan (5.66 × 109/L) and non Papuan (7.20 × 109/L) patients Figure 2
The mean (95% CI) total white cell counts in vivax infected Papuan (5.66 × 109/L) and non Papuan (7.20 × 109/
L) patients. The mean difference at baseline is -1.54 (-0.47 to -2.62) × 109/L, P = 0.0055].
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Discussion
These analyses have shown that at presentation the major-
ity of malaria infected patients had total white cell counts
within the normal range and most were thrombocyto-
paenic. By Day 28, both mean counts had increased but
thrombocytopaenia remained in just over 20% of
patients. These data complement and are broadly consist-
ent with those of other clinical series.
Data from this study were from two dissimilar groups
with respect to ethnicity and the degree of malaria
acquired immunity. The Papuans had life long malaria
exposure whilst the non Papuans had limited or no
malaria exposure. The Papuans had lower mean Day 0
white counts than the non Papuans and there was a nota-
ble difference in the WCC changes over time. They rose
steadily in the Papuans but fell significantly on Day 3 in
the non Papuans, consistent with a study of experimen-
Mean (95% CI) platelet counts of malaria infected Papuans and non Papuans as a function of a palpable spleen Figure 3
Mean (95% CI) platelet counts of malaria infected Papuans and non Papuans as a function of a palpable spleen.
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The mean (95% CI) platelet counts in falciparum infected Papuan and non Papuan patients Figure 4
The mean (95% CI) platelet counts in falciparum infected Papuan and non Papuan patients.
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tally induced falciparum malaria in malaria naïve Ameri-
can volunteers [2]. By Day 28, the mean WCCs in the non
Papuans had caught up and both groups had similar
mean WCCs. This difference in the WCC progressions
between the two ethnic groups is difficult to explain
purely on the basis of a redistribution of white cells and/
or splenic sequestration, given that the malaria naïve non
Papuans had significantly less splenomegaly. These data
might indicate that a lesser degree of malaria exposure,
thus acquired immunity, in the non Papuans resulted in a
more robust inflammatory response, reflected crudely by
a higher, baseline total WCC [27]. The initial fall in the
total WCC in the non Papuans might reflect a difference
in response to dying parasitized red cells consequent to
treatment.
Thrombocytopaenia was common at presentation in both
groups of patients. There were no differences between the
Papuans and non Papuans but the mean platelet count
was lower in vivax compared to falciparum infected
patients. There were negative correlations between the
Day 0 platelet count and the falciparum parasite count
and the Day 0 temperature in the vivax patients. These
findings are consistent with some but not other reports
and are of limited clinical value [2,4,8,31,34]. Over time,
the mean platelet count increased, consistent with the
findings of others but two reports document an initial fall
in the platelet count followed by recovery [2,4]. The mean
platelet count appeared higher on Day 7 compared to Day
28 but there are no intervening platelet counts, so the day
of the mean peak platelet count cannot be determined.
Some 20% of patients were still thrombocytopaenic by
study end, suggesting a number of patients need longer
than four weeks for full platelet recovery. The multivariate
analysis found drug arm to be significant factor for the
Day 7 platelet count with the combination arm having a
higher mean platelet count than the doxycycline arm. This
is of little clinical significance.
Our study had limitations. The study sample was small
and powered for a clinical trial. The data presented were
secondary analyses to look for possible Papuan non
Papuan differences. Many patients failed treatment before
Day 28, given rescue treatment and withdrawn from the
study; this may have introduced a statistical bias. Most
patients were male, thus limiting the applicability of the
findings. There were many statistical comparisons and
some significant results may have occurred by chance. The
differential white cell count was not measured and could
have provided additional interesting data.
Conclusion
To conclude, these analyses have compared and con-
trasted the changes in the total white cell and platelet
counts in Papuans and non Papuans with different
degrees of malaria exposure that may partly explain the
difference in the mean total white cell count at presenta-
tion between the two groups.
The mean (95% CI) platelet counts in vivax infected Papuan and non Papuan patients Figure 5
The mean (95% CI) platelet counts in vivax infected Papuan and non Papuan patients.
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